<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318"><gtr:id>5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318</gtr:id><gtr:name>Astex Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F62D14B6-E917-49C9-ABB4-5AEF64C8900E"><gtr:id>F62D14B6-E917-49C9-ABB4-5AEF64C8900E</gtr:id><gtr:name>Tokai Pharmaceuticals Inc</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Northern Institute for Cancer Research</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318"><gtr:id>5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318</gtr:id><gtr:name>Astex Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F62D14B6-E917-49C9-ABB4-5AEF64C8900E"><gtr:id>F62D14B6-E917-49C9-ABB4-5AEF64C8900E</gtr:id><gtr:name>Tokai Pharmaceuticals Inc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/584EC7A6-0F03-413E-A444-AD288D6E29DC"><gtr:id>584EC7A6-0F03-413E-A444-AD288D6E29DC</gtr:id><gtr:firstName>Craig</gtr:firstName><gtr:otherNames>Nigel</gtr:otherNames><gtr:surname>Robson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7ECC515F-3237-4790-A8F7-69D2E0BBC480"><gtr:id>7ECC515F-3237-4790-A8F7-69D2E0BBC480</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:surname>Loddick</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/41DFFD5E-5265-4C99-AEFE-925ADDEEFE49"><gtr:id>41DFFD5E-5265-4C99-AEFE-925ADDEEFE49</gtr:id><gtr:firstName>Nigel</gtr:firstName><gtr:surname>Brooks</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C6073C42-2A55-4B9D-B5E3-AC1C591D907E"><gtr:id>C6073C42-2A55-4B9D-B5E3-AC1C591D907E</gtr:id><gtr:firstName>Luke</gtr:firstName><gtr:surname>Gaughan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0800889"><gtr:id>D99B763B-D8E2-47B4-B6DB-1E4E38990419</gtr:id><gtr:title>Characterisation of a novel series of small molecule androgen receptor modulators in prostate cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800889</gtr:grantReference><gtr:abstractText>Prostate cancer causes approximately 10,000 deaths in the UK each year. Current treatments attempt to prevent the action of the androgen receptor, a protein that drives prostate cancer growth. Unfortunately, these treatments are not effective in the long-term and the generation of disease that no longer responds to this therapy, termed hormone-refractory prostate cancer (HRPC), is common and often fatal. Therefore, the key goal for researchers is to develop new drugs that can be used to treat this disease.

The androgen receptor remains an important driving force in the development of HRPC and therefore the generation of new agents that can permanently block it?s function are necessary to effectively treat the disease. 

This project will study the effect of a new panel of drugs that can inactivate the androgen receptor in several model systems of HRPC. These studies will provide important information regarding the effect of these agents on androgen receptor action and growth of prostate cancer cells. Ultimately, this work will be important for determining the effectiveness of these drugs as future therapies for prostate cancer treatment.</gtr:abstractText><gtr:technicalSummary>Prostate cancer (CaP) causes approximately 10,000 deaths per year in the UK alone. Current treatments for the disease attempt to inactivate the androgen receptor (AR), a member of the nuclear hormone receptor family of transcription factors, that regulates genes involved in prostate growth and transformation. Initial response to androgen-ablation therapy is good, but in most cases, the cancer recurs in a more aggressive form that is no longer responsive to hormonal therapy and is termed hormone-refractory prostate cancer (HRPC). There is a requirement therefore to develop new treatments that are effective against HRPC.

The fact that the AR is expressed and functional in HRPC, and is important for tumour expansion, indicates that the receptor remains a prominent target for therapy. Therefore, attenuating the function of the AR via distinct, non-conventional mechanisms in HRPC by novel receptor modulators is one avenue of research that requires attention.

AstraZeneca have identified a series of novel compounds that reduce AR activity in vivo as demonstrated by attenuation of testosterone stimulated growth of sexual accessory organs in both immature weanling rats and in mature castrated rats. Importantly, preliminary studies in vitro and in vivo indicate that the mechanism of repression is distinct from currently used adjuvant therapies and may lead to efficacy in HRPC. Further characterisation of these compounds is therefore vital for translation into the clinical setting. 

To this end, we plan to perform the following experiments:

i. The effect of these novel AR modulators on transcriptional activity and cellular movement of the receptor will be assessed using a panel of CaP cell line models that mimic androgen-dependent and HRPC disease. We will also assess receptor turnover in response to compound treatment and identify enzymes responsible for driving modulator activity. 

ii. The efficacy of the novel agents will be assessed in vivo using either subcutaneous xenograft or hollow fibre models of HRPC, incorporating androgen-insensitive cell lines. Tumour growth and proliferation will be determined and ex vivo analysis of disease markers will be performed by immunohistochemistry. 

Ultimately, this study will characterise the efficacy of these novel AR modulators in both in vitro and in vivo models that will be a major step towards the generation of a new and much needed treatment for HRPC.</gtr:technicalSummary><gtr:fund><gtr:end>2011-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>409180</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AZ link</gtr:description><gtr:id>3838968E-E2BA-4B08-9001-BC13583D67E3</gtr:id><gtr:impact>Newly funded PhD studentship</gtr:impact><gtr:partnerContribution>Collaborator visits and access to resources at partner sites and exchange of materials</gtr:partnerContribution><gtr:piContribution>Supply of reagents and expert advise and planning of a series of experiments</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tokai Pharmaceuticals Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Tokai - anti-androgen therapy</gtr:description><gtr:id>AD8ABE3B-C7C8-47FA-AF60-7F6F19B7F0A9</gtr:id><gtr:impact>Funded research in our laboratories to explore Tokai small molecules and to develop more potent small molecules that are beneficial in prostate cancer therapy</gtr:impact><gtr:partnerContribution>Provide small molecules for study in collaboration</gtr:partnerContribution><gtr:piContribution>Identified a deubiquitinase enzyme that is targetted by small molecule anti-androgen produced by Tokai</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Astex Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Astex Therapeutics</gtr:department><gtr:description>Astex Collaboration</gtr:description><gtr:id>BC2324F4-A9CB-4C8A-AA57-42789E56B6D7</gtr:id><gtr:impact>Preliminary data on screening for inhibitors of androgen receptor inhibitors in prostate cancer</gtr:impact><gtr:partnerContribution>Access to fragment based design of small molecule inhibitors.
Structural Biology.</gtr:partnerContribution><gtr:piContribution>Reagents, established expertise</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Robson 24 hr Run</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>299E6A92-A5C4-4328-9175-606BA457AE6B</gtr:id><gtr:impact>Robson provided 15 minute presentation of NICR research and held 1 to 1 discussions with cancer sufferers/survivors and their friend and families.

Increased fundraising potential and provided accurate information for public interested in cancer research</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit - Gaughan</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F5BF36B8-B61B-431F-81E6-7A3C0079BE47</gtr:id><gtr:impact>Gaughan as RC UK Fellow had meetings with local teachers to discuss workshops for school students. Presentations from Gaughan to teachers. Outreach being extended to presentations to school children.

Continuing programme to encourage students from underachieving schools to engage with science</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Movember Fundraising - Prostate Cancer Awareness</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F996832F-AD23-4508-8BA9-FDA1D47E0DD9</gtr:id><gtr:impact>Approx 100 workers from Proctor and Gamble PLC made aware of prostate cancer (briefly mentioned other cancers) risk factors and nature of research programme to combat disease

2012 gave two talks to different groups and this stimulated a series of talks for 2013 and additional events related to fundraising and public awareness of prostate cancer</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.uk.pg.com   http://uk.movember.com/</gtr:url><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Various Fundraising evenings</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F18F37FC-9A79-404E-8F38-3FFDAC42348D</gtr:id><gtr:impact>Mostly evening, some weekend events where local fundraisers contributions are acknowledged. Generally short presentation made and sometimes receive cheque. Local press often in attendance for interview and photograph

Raise importance of cancer research</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Outreach High School Interaction</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F94296D4-33A6-4BFF-B58C-45D312874242</gtr:id><gtr:impact>Series of workshops with Science School Teachers (5-20 participants)

Introduction of current science research and update on current research technologies</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cancer fund raising event</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>402C998B-7957-401B-9080-9F4ABA011D36</gtr:id><gtr:impact>Short talk on research highlights to date

Positive interaction with patient groups and stimulated their further interest to lobby government , MPs and specific prostate charities to devote more monies to this research area</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Institute Open Days</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2A26AFB8-62A8-4BF3-91E7-51AAC8EF381F</gtr:id><gtr:impact>3-4 hour planned session, 2-3 times yearly, on a Saturday morning. Visits of approx 100 members of public. Short presentations and demonstrations of equipment by 4-6 research groups. Closing with 1 to 1 discussions over coffee/tea.

Contact maintained with several individual members of public</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Charity Fun Run</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>ED8EC3C7-612D-48F8-BD2B-4E9F8BE5101A</gtr:id><gtr:impact>Short presentation of research to large audience (primarily female) of between 3000-6000 audience. Including interviews with local press and local radio.

Informal discussions with smaller groups of cancer sufferers/ survivors and patient representative group</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Shaheen Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9FA72731-C36F-425B-B030-5BF3628F9C0A</gtr:id><gtr:impact>Open Day presentations. Series of laboratory tours and demonstrations to interested public

Accurate communication of our research</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Dr William Edmund Harker Foundation</gtr:department><gtr:description>Sir William Edmond Harker Foundation</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Newcastle University</gtr:fundingOrg><gtr:id>5D68FE26-0B63-441F-AFBC-795EF169822F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>198000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PCC Project grant</gtr:description><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>7310BC6F-1ACE-4FDC-B811-106479438E0B</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>130000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Newcastle Cancer Centre - Astra Zeneca</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>E3E1819B-DDBD-40EA-868D-1F695B282847</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Novel inhibitors of androgen receptor function in prostate cancer</gtr:description><gtr:id>286ABB53-0CFD-4192-8D87-0E216AD4A91A</gtr:id><gtr:impact>Potential for use in advanced prostate cancer treatment</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>Insufficient Information</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Inhibitors of androgen receptor in prostate cancer</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NCRI Biomarkers and Imaging Group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4314CB27-6119-4FF7-B3B6-21FBD29F0A63</gtr:id><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Drug for potential use in treatment of advanced prostate cancer</gtr:description><gtr:id>45381986-2F8C-4DFA-A055-B886A276B6DB</gtr:id><gtr:impact>New therapeutic drug to be included in the treatment of advanced prostate cancer</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>AZ inhibitors of AR</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>NCT01162395</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Anti-androgen resistant LNCaP variants</gtr:description><gtr:id>45DA6919-60D5-4A17-BE9C-8C05817B871C</gtr:id><gtr:impact>Useful for in vivo model studies</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>LNCaP Variants</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Drug developed by Astra Zeneca partner. Detailed characterisation of lead drug and derived drugs led to selection of drug for clinical trials in prostate cancer</gtr:description><gtr:id>EFEB8284-A371-45CD-8617-095E49BB64F9</gtr:id><gtr:impact>Potential use as a drug for treatment of advanced prostate cancer</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Clinical trial of prostate cancer drug</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Integration of AZ and Newcastle research platforms</gtr:description><gtr:id>C6CA98AF-94D0-4EA8-95EE-BCF60ACA96E2</gtr:id><gtr:impact>Speeded up research development, integration across 2 collaborating sites</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Standardised platforms</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Generated mutant derivatives of Androgen Receptor plasmids</gtr:description><gtr:id>70437607-A97A-43E8-8385-26C296FE97A6</gtr:id><gtr:impact>Useful reagents for target validation</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>AR mutants</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Novel assays developed for research project</gtr:description><gtr:id>BB326074-89FA-4D8C-95B6-FC2A04385027</gtr:id><gtr:impact>Efficient assay development. Reproducible, reliable and high throughput assay at lower cost than previously developed</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Assay development</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5FCC1630-A97A-4CBF-97E8-37C2955DE19B"><gtr:id>5FCC1630-A97A-4CBF-97E8-37C2955DE19B</gtr:id><gtr:title>The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ba75dc69144818b02846de1303bf67a5"><gtr:id>ba75dc69144818b02846de1303bf67a5</gtr:id><gtr:otherNames>Coffey K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AF03E510-2727-4483-A5C7-DBBF4B2E7610"><gtr:id>AF03E510-2727-4483-A5C7-DBBF4B2E7610</gtr:id><gtr:title>AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d5744838b41b854700310dabdefc0b2e"><gtr:id>d5744838b41b854700310dabdefc0b2e</gtr:id><gtr:otherNames>Loddick SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/46E9E163-BF8B-4E73-A1DF-3DA92CCA3C2C"><gtr:id>46E9E163-BF8B-4E73-A1DF-3DA92CCA3C2C</gtr:id><gtr:title>Deubiquitinating enzyme Usp12 is a novel co-activator of the androgen receptor.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5911ce2f2ce71b2e98bcf7b340bfcce8"><gtr:id>5911ce2f2ce71b2e98bcf7b340bfcce8</gtr:id><gtr:otherNames>Burska UL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F06DE7EC-8EDA-4876-A647-8A633331AEAF"><gtr:id>F06DE7EC-8EDA-4876-A647-8A633331AEAF</gtr:id><gtr:title>Targeting the DNA double strand break repair machinery in prostate cancer.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b2b0adef03f787668da195c394b18f93"><gtr:id>b2b0adef03f787668da195c394b18f93</gtr:id><gtr:otherNames>Shaheen FS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5E7ECE66-AD7B-41F7-B51D-70987276492E"><gtr:id>5E7ECE66-AD7B-41F7-B51D-70987276492E</gtr:id><gtr:title>Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4ed6f4f497449fe1878010c3b6afd47e"><gtr:id>4ed6f4f497449fe1878010c3b6afd47e</gtr:id><gtr:otherNames>Jones D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C5B4DC4F-E57B-459E-95AC-2DE4641846D9"><gtr:id>C5B4DC4F-E57B-459E-95AC-2DE4641846D9</gtr:id><gtr:title>Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f68a702ef5ec550ca56df961f101e510"><gtr:id>f68a702ef5ec550ca56df961f101e510</gtr:id><gtr:otherNames>Logan IR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7FB19601-E49B-4FFA-9FD9-434BF8462163"><gtr:id>7FB19601-E49B-4FFA-9FD9-434BF8462163</gtr:id><gtr:title>Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Gynecologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/41f1ca20ef5f14be6786383c0c27fc84"><gtr:id>41f1ca20ef5f14be6786383c0c27fc84</gtr:id><gtr:otherNames>Elattar A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0090-8258</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800889</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>